NASDAQ:ALLR

Allarity Therapeutics Q1 2025 Earnings Results & Report

Allarity Therapeutics logo
$0.84 -0.03 (-3.91%)
Closing price 04:00 PM Eastern
Extended Trading
$0.89 +0.05 (+5.35%)
As of 04:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Allarity Therapeutics beat analyst earnings expectations in its Q1 2025 results, released May 13, 2025. The company reported EPS of -$0.25 versus the -$8.10 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens

Allarity Therapeutics EPS Results

Actual EPS
-$0.25
Consensus EPS
-$8.10
Beat/Miss
Beat by +$7.85
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 7 quarters

Allarity Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Allarity Therapeutics Q1 2025 Earnings FAQ

Allarity Therapeutics (NASDAQ:ALLR) reported earnings of -$0.25 per share for Q1 2025, beating the consensus estimate of -$8.10. The report was announced on Tuesday, May 13, 2025.

Allarity Therapeutics Earnings Headlines

Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
Allarity Therapeutics (NASDAQ:ALLR) Releases Q4 2026 Earnings Guidance
Allarity Therapeutics (NASDAQ:ALLR) Announces FY 2026 Earnings Guidance
See More Allarity Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Allarity Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Allarity Therapeutics and other key companies, straight to your email.

About Allarity Therapeutics

Allarity Therapeutics (NASDAQ:ALLR) is a biotechnology company focused on developing precision-medicine treatments for cancer. Its approach combines oncology drug development with tools intended to help identify patients who may be more likely to respond to a particular therapy.

The company’s Drug Response Predictor (DRP) technology analyzes gene-expression data to estimate how a patient’s tumor may respond to a drug. Allarity has developed the platform for use in selecting patients for clinical studies and as a potential companion diagnostic.

One of Allarity’s drug candidates is stenoparib, an oral therapy that inhibits PARP and tankyrase proteins and has been studied for ovarian cancer. The company’s work centers on advancing cancer treatments alongside diagnostic tools designed to support more individualized treatment decisions.

View Allarity Therapeutics Profile